Imagi ng of gastric cancer with 18 F-FDG PET is limited because of the relatively high number of primary tumors that are not avid for 18 F-FDG (4%-53%), making primary staging and early evaluation of response to treatment impossible (1) (2) (3) (4) (5) . Published sensitivities for 18 F-FDG PET range from 47% to 96% (mean sensitivity, 77%; mean specificity, 99%) for the detection of gastric cancer and from 23% to 73% (mean sensitivity, 45%; mean specificity, 92%) for the detection of lymph node involvement (1) (2) (3) (4) (5) . 18 F-FDG uptake has been shown to be lower in cancers of the nonintestinal type, with signet ring cells, high mucinous content, and lower cellularity (3, 6, 7) .
To increase sensitivity and specificity for gastric cancer, other tracers that complement the information provided by 18 F-FDG are required. Increased proliferative activity has been shown to be potentially more specific for malignant tumors than are alterations of glucose metabolism (8) . Therefore, measurement of tumor growth and DNA synthesis in vivo might be superior for imaging malignancies of the gastrointestinal tract. Recently, the pyrimidine analog 39-deoxy-39- 18 F-fluorothymidine (FLT) has been reported to be a stable PET tracer that accumulates in proliferating tissues and malignant tumors (9) . 18 F-FLT is a substrate for thymidine kinase 1, which is a key enzyme in the salvage pathway for the producing of thymidine monophosphate and has been assessed for its potential role in imaging thymidylate synthase inhibition (10) (11) (12) . Several human studies recently demonstrated the feasibility of 18 F-FLT PET for imaging gastrointestinal cancers (13) (14) (15) .
In this pilot study, we investigated the feasibility of 18 F-FLT PET, in comparison to 18 F-FDG PET, for imaging locally advanced gastric cancer. Furthermore, we examined the correlation of 18 F-FLT uptake with the histologic subtype and location of the tumor.
MATERIALS AND METHODS

Patient Population
Forty-five consecutive patients with an initial diagnosis of locally advanced gastric cancer and meeting the eligibility requirements (presence of biopsy-proven gastric cancer with or without clinical evidence of locoregional lymph node metastases and with a tumor stage of T3-4, Nx, M0, according to the TNM classification system) were included in this prospective study (31 men and 14 women; mean age, 61 6 11 y; range, 36-78 y). Staging procedures included endoscopy, endoscopic ultrasound, and CT of the chest, abdomen, and pelvis in all patients and additional laparoscopy in some patients. Tumors were localized with endoscopy and-if available and detectable-CT. Patients with an Eastern Cooperative Oncology Group score of less than 1, uncontrolled bleeding from the tumor, gastric outlet syndrome, or an age of less than 18 y were excluded. Details of the study were explained by a physician, and written informed consent was obtained from all patients. The study protocol was approved by the local ethics committee of the Technische Universität München.
Histologic Classification
For histopathologic evaluation of the biopsy samples, the Lauren classification, tumor grading (microscopic growth type), and World Health Organization classification were applied. Tumor location was defined according to the findings on endoscopy and CT. In this study, a modified Lauren classification was used. This classification differentiates only between intestinal (gland formation) and nonintestinal tumors. This modification facilitates the classification based on biopsy and thereby decreases interobserver variability (7, 16 ).
F-FLT PET
18 F-FLT was synthesized as previously described (17) . Imaging was performed on a whole-body high-resolution PET scanner (ECAT HR1; Siemens/CTI). This scanner simultaneously acquires 47 contiguous slices with a slice thickness of 3.4 mm. The in-plane image resolution of transaxial images was approximately 8 mm in full width at half maximum, with an axial resolution of approximately 5 mm in full width at half maximum.
A dynamic 45-min acquisition began simultaneously with the injection of approximately 300 MBq of 18 F-FLT (range, 270-340 MBq). Twelve 10-s frames, three 1-min frames, and eight 5-min frames were acquired. After the dynamic phase, static emission images were acquired covering the abdominal and pelvic area (2-dimensional mode, 4-5 bed positions, 8 min for each). Emission data were corrected for random coincidences, dead time, and attenuation and were reconstructed by filtered backprojection (Hanning filter with a cutoff frequency of 0.4 cycles per bin). The matrix size was 128 · 128 pixels, with a pixel size of 4.0 · 4.0 mm. The image pixel counts were calibrated to activity concentrations (Bq/mL) and decay-corrected using the time of tracer injection as the reference.
F-FDG PET/CT
Patients underwent 18 F-FDG PET/CT on a Biograph Sensation 16 scanner (Siemens Medical Solutions). The CT protocol included acquisition of a low-dose CT scan (26 mAs, 120 kV, 0.5 s per rotation, and 5-mm slice thickness) from the base of the skull to the mid thigh for attenuation correction, with use of diluted oral contrast material (sodium meglumine ioxithalamate, 300 mg), followed by the PET scan. All PET scans were acquired in 3-dimensional mode with an acquisition time of 3 min per bed position. Forty-seven contiguous slices were acquired per bed position, and the matrix size was 128 · 128, with a slice thickness of 3.4 mm. Images were reconstructed using attenuation-weighted ordered-subsets expectation maximization algorithm (4 iterations and 8 subsets) followed by a postreconstruction smoothing gaussian filter (5 mm in full width at half maximum). Patients fasted at least 6 h before the PET scan, and blood glucose levels were measured before administration of 18 F-FDG. All measured values were less than 150 mg/dL. Static emission imaging was performed 60 min after intravenous injection of 300-370 MBq of 18 F-FDG. Emission data were corrected for randoms, dead time, scatter, and attenuation, and the same reconstruction algorithm was applied as for the conventional PET data.
PET Data Analysis
All 18 F-FLT PET scans were evaluated by 2 experienced nuclear medicine physicians who were unaware of the clinical data and the results of other imaging studies. Circular regions of interest (ROIs) with a diameter of 1.5 cm were placed in the area with the highest tumor activity as described earlier (18) . Mean standardized uptake values (SUVs) were calculated from each ROI using the following formula: SUV 5 measured activity concentration (Bq/g) · body weight (g)/injected activity (Bq). ROIs were also placed in reference segments of the following organs: liver, bone marrow, and muscle. For definition of ROIs and data analysis, computer programs developed in the Interactive Data Language (IDL; Research Systems, Inc.) using the Clinical Application Programming Package (CAPP; Siemens/CTI, Inc.) (19) . 18 F-FDG PET/CT scans were semiquantitatively evaluated by circular ROIs (diameter, 1.5 cm) with the eSOFT software (Siemens Medical Solutions) and normalized for injected dose and the patient's body weight.
Statistical Analysis
Statistical analyses were performed using SPSS software (version 14.0; SPSS, Inc.). Quantitative values were expressed as mean 6 SD, median, and range. Related metric measurements were compared using the Wilcoxon signed rank test and the Mann-Whitney U test in the case of 2 independent samples. The Fisher exact test was used for comparison of frequencies, and Spearman correlation coefficients were calculated to quantify bivariate correlations of measurement data. All analyses were 2-sided, and a P value of less than 0.05 was considered statistically significant.
RESULTS
Patients
The primary tumor was located in the proximal third of the stomach in 28 patients (62%), in the middle third in 9 patients (20%), and in the distal third in 8 patients (18%). According to the Lauren classification, 15 tumors (33%) were of the intestinal subtype and 30 (67%) of the nonintestinal subtype. Most tumors (78%) were poorly differentiated (grade 3 or 4 of 4). The endoscopic tumor category
Visual Interpretation of Gastric Cancer with 18 F-FLT PET and 18 F-FDG PET/CT
In the 45 patients undergoing an initial 18 F-FLT PET scan, all tumors showed focal uptake of 18 F-FLT, resulting in a sensitivity of 100%. Background activity was low for 18 F-FLT, resulting in a high tumor-to-background contrast. In the 18 F-FDG PET/CT scan, only 31 of 45 tumors could be detected visually, resulting in a sensitivity of 69% and a significantly lower detection rate than for 18 F-FLT (P , 0.01) ( Table 1) . Uptake in the 18 F-FDG-avid tumors was much higher than the physiologically variable uptake in the gastric wall.
Semiquantitative Evaluation of 18 F-FLT Uptake and Biodistribution
In all 45 patients, focal 18 F-FLT uptake could be detected in the region of histologically proven gastric cancer. The mean 18 F-FLT uptake ( 18 F-FLT SUV) of the tumor sites was 6.0 6 2.5 (median, 5.3; range, 2.4-12.7). Besides tracer accumulation in the tumor, high physiologic 18 F-FLT uptake in proliferating bone marrow was observed (mean SUV, 7.4; median, 7.2; range, 3.7-10.6). The mean 18 F-FLT SUV in a reference segment was 5.3 for liver (median, 4.9; range, 2.9-13.2) and 0.9 for muscle (median, 0.9; range, 0.4-1.3). Figure 1 illustrates the biodistribution of 18 F-FLT in patients with gastric cancer.
Focal 18 F-FLT uptake in the tumor sites showed no significant dependence on location (proximal third, 6.1, vs. distal thirds, 5.9; P 5 0.87), Lauren classification (intestinal subtype, 7.1, vs. nonintestinal subtype, 5.5; P 5 0.11), or presence of mucinous cells (mucin-positive, 6.1, vs. mucin-negative, 6.0; P 5 0.65). In contrast, the subgroup of tumors with signet ring cells had a significantly lower 18 F-FLT uptake than did tumors without signet ring cells (5.4 vs. 7.0; P 5 0.05).
Imaging with 18 F-FDG PET/CT
In 14 of the 45 patients, the primary tumor was not detectable with 18 18 F-FDG uptake than did tumors without signet ring cells (6.4 vs. 10.7; P , 0.01). Additionally, tumoral 18 F-FDG uptake correlated significantly with the Lauren classification. Tumors of the intestinal subtype had a significantly higher 18 F-FDG uptake than did nonintestinal tumors (10.5 vs. 7.2; P , 0.01). In contrast, a difference in uptake dependent on the location (8.3 vs. 8.9; P 5 0.62) and on the presence of mucinous content (8.3 vs. 8.5; P 5 0.48) was not statistically significant.
Comparison of 18 F-FLT and 18 F-FDG Uptake
Analyzing all patients with an 18 F-FDG uptake in gastric cancer higher than background activity (n 5 31) showed a significant correlation between the mean SUVs of the 2 radiotracers studied ( 18 F-FLT, 6.8 6 2.6, vs. 18 F-FDG, 8.4 6 4.1; r 5 0.46; P , 0.01) (Figs. 2 and 3) . Despite this correlation, initial 18 F-FDG uptake was significantly higher than initial 18 F-FLT uptake for both mean SUV (P 5 0.03) and maximum SUV (7.8 6 3.0 vs. 11.5 6 5.6; P , 0.01). In contrast, in the subgroup of signet ring cell-positive tumors (n 5 27), there was no significant difference between 18 F-FLT and 18 F-FDG uptake as indicated by mean SUV ( 18 F-FLT, 6.2 6 2.1, vs. 18 F-FDG, 6.4 6 2.8; P 5 0.94) or by maximum SUV ( 18 F-FLT, 7.2 6 2.6, vs. 18 F-FDG, 8.4 6 3.4; P 5 0.07). Uptake of the 2 tracers showed no significant correlation in this subgroup (r 5 0.38; P 5 0.15) (Fig. 2) . In the subgroup of 18 F-FDG-negative tumors, the mean SUV of focal 18 F-FLT uptake was 4.2 6 1.2 (Table 1) .
DISCUSSION
This clinical study demonstrated the potential of 18 F-FLT PET for imaging gastric cancer. In contrast to the standard (14, 20) . Interestingly, even 18 F-FDG-negative tumors with signet ring cells or mucinous content were detected by 18 F-FLT PET. Compared with tumors responding to neoadjuvant chemotherapy (as indicated by a rapid decrease in tumoral 18 F-FDG uptake), signet ring cell-positive tumors are characterized by a different biological behavior resulting in lower response rates and impaired prognosis (21) . Increased consumption of glucose is characteristic of most cancers and is in part related to overexpression of glucose transporters (22) . As rationale for 18 F-FDG-negative gastric tumors, it has been postulated that the low or absent 18 F-FDG uptake in the nonintestinal subtype results from the high number of signet ring cells, leading to a reduced 18 F-FDG concentration in the tumor. Another reason could be the lack of expression of the glucose transporter Glut-1 on the cell membrane of most nonintestinal gastric cancer tumors (23) .
There was also a trend toward lower detection rates of 18 F-FDG PET in the middle and distal thirds than in the proximal third of the stomach (P 5 0.07, nonsignificant). This observation could be explained by the low or absent 18 F-FDG uptake in the nonintestinal subtype resulting from the high number of signet ring cells. Compared with intestinal gastric cancer, nonintestinal gastric cancer shows a higher chromosomal stability, which might lead to a lower proliferation rate. Nonintestinal gastric cancer is characterized by a lower fractional allelic loss and a lower loss of heterozygosity being inversely correlated with the methylation rate (24) . Nonintestinal tumors with a high methylation rate and low fractional allelic loss and loss of heterozygosity tend to have a worse prognosis than do intestinal tumors (24, 25) . Chromosomally stable tumors might show lower proliferative activity. Therefore, antiproliferative agents might be less effective, potentially leading to lower response rates in nonintestinal tumors.
In contrast to 18 F-FDG, 18 F-FLT PET specifically reflects activity of thymidine kinase 1, the key enzyme of the salvage pathway for producing thymidine monophosphate. The level of thymidine kinase 1 protein has proven to be an important determinant of 18 F-FLT uptake in tumors. However, the detailed uptake mechanism remains to be determined. A recent study showed that 18 F-FLT PET can be used to measure thymidylate synthase inhibition in tumors early after drug administration, indicating a potential use of 18 F-FLT for early measurement of antiproliferative drug effects (26) . There was a trend toward lower tumoral 18 F-FLT uptake in nonintestinal than intestinal tumors, according to the Lauren classification. However, the presence of signet ring cells was the only histopathologic factor significantly influencing uptake of 18 F-FLT, as was also shown previously for 18 F-FDG (21) .
Several limitations have to be considered when our results are transferred to the clinic. Our results apply to a specific group of patients with a high proportion of signet ring cellcontaining tumors, reflecting a patient selection different from that of previous studies (21) . However, the fact that our results were found exactly for this group of patients indicates that 18 F-FLT PET may be used for imaging gastric cancer containing signet ring cells-a histologic subtype with a markedly reduced sensitivity on 18 F-FDG PET. Furthermore, the impact of 18 F-FLT PET for imaging locally advanced gastric cancers is rather limited considering that detection and diagnosis of gastric cancer remains the domain of conventional imaging modalities such as endoscopy, endoscopic ultrasound, and CT. However, studies investigating the role of 18 F-FLT PET for monitoring therapy of gastric cancers may strongly influence clinical management.
Our study documents that 18 F-FLT PET is a feasible tool for imaging tumors of an unfavorable histologic type (signet ring cell carcinoma) and low 18 F-FDG uptake. 18 F-FDG has been used successfully for treatment monitoring of adenocarcinomas of the esophagogastric junction and gastric cancers (14, 20, 21, 27, 28) . However, some tumors have uptake insufficient to provide the image contrast needed for quantitative analysis of 18 F-FDG PET. This pilot study provides the rationale for future use of 18 F-FLT for treatment monitoring because all primaries could be visualized with 18 F-FLT, suggesting that 18 F-FLT PET can be used to tailor treatment to the chemosensitivity of an individual tumor.
CONCLUSION
In summary, this clinical study compared 18 F-FLT PET with 18 F-FDG PET for the detection of locally advanced gastric cancer. 18 F-FLT PET had a higher sensitivity than 18 F-FDG PET and might serve as a useful diagnostic adjunct for the quantitative assessment of proliferation. In the future, the addition of 18 F-FLT PET to 18 F-FDG PET could improve early evaluation of the response to neoadjuvant treatment of gastric cancer. 
